title: Multiple myeloma, version 1.2013.
abstract: These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.
authors: Dana-Farber Cancer Institute/Brigham and Women's Cancer Center.
authors: Kenneth C
authors: KC
authors: Anderson
authors: Melissa
authors: M
authors: Alsina
authors: William
authors: W
authors: Bensinger
authors: J Sybil
authors: JS
authors: Biermann
authors: Adam D
authors: AD
authors: Cohen
authors: Steven
authors: S
authors: Devine
authors: Benjamin
authors: B
authors: Djulbegovic
authors: Edward A
authors: EA
authors: Faber
authors: Cristina
authors: C
authors: Gasparetto
authors: Francisco
authors: F
authors: Hernandez-Illizaliturri
authors: Carol Ann
authors: CA
authors: Huff
authors: Adetola
authors: A
authors: Kassim
authors: Amrita Y
authors: AY
authors: Krishnan
authors: Michael
authors: M
authors: Liedtke
authors: Ruby
authors: R
authors: Meredith
authors: Noopur
authors: N
authors: Raje
authors: Jeffrey
authors: J
authors: Schriber
authors: Seema
authors: S
authors: Singhal
authors: George
authors: G
authors: Somlo
authors: Keith
authors: K
authors: Stockerl-Goldstein
authors: Steven P
authors: SP
authors: Treon
authors: Donna
authors: D
authors: Weber
authors: Joachim
authors: J
authors: Yahalom
authors: Furhan
authors: F
authors: Yunus
authors: Dorothy A
authors: DA
authors: Shead
authors: Rashmi
authors: R
authors: Kumar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D009842:Oligopeptides / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000628:therapy; D017410:Practice Guidelines as Topic; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077337:Vorinostat
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D006877:Hydroxamic Acids; D009588:Nitrogen Mustard Compounds; D009842:Oligopeptides; D011719:Pyrazines; D013792:Thalidomide; D000077337:Vorinostat; D000069286:Bortezomib; C524865:carfilzomib; D003907:Dexamethasone; D000069461:Bendamustine Hydrochloride; D000077269:Lenalidomide